A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and Abdomen
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Other
Enrollment
67actual
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-16 | actual | When the study began enrolling |
| Primary completion | 2025-07-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-24 | actual | The whole study's end, after follow-up |
| First posted | 2021-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Intervention
- Combination product: Sayana Press — also filed as Medroxyprogesterone
Primary outcomes
what the primary-completion date above is the date OFSerum Trough Concentration (Ctrough) of Medroxyprogesterone
measured Day 92 post dose
Area under the curve from time zero to end of dosing interval (AUCtau)
measured pre-dose, up to 92 days post dose
Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone
measured pre-dose, up to 92 days post dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed